SNDX - Syndax Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Syndax Pharmaceuticals, Inc.

Building D
Floor 3 35 Gatehouse Drive
Waltham, MA 02451
United States
781-419-1400
http://www.syndax.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees44

Key Executives

NameTitlePayExercisedYear Born
Dr. Briggs W. MorrisonCEO & Director872.68kN/A1960
Mr. Michael A. MetzgerPres & COO731.86kN/A1971
Mr. Richard P. SheaCFO, Treasurer & Principal Accounting Officer39kN/A1952
Dr. Michael L. Meyers M.D., Ph.D.Chief Medical Officer and Sr. VP550.81kN/A1951
Dr. Peter OrdentlichCo-Founder & CTON/AN/A1969
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Syndax Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.